StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $173M in Q3 2026, up 78.4% from a year earlier. That is the highest of the 27 quarters on record here.

Latest, Q3 2026
173
Period ended Sep 30, 2026
Change on a year earlier
+78.4%
97 in Q3 2025
History
27 quarters
Since Q1 2020
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Zolgensma Group | Neuroscience | Spinal muscular atrophy (SMA) | 173 | 78 | 231 | 13 | 14 | 404 | 34 | 35”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 2026173+78.4%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026152+58.3%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026117-9.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202591-5.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202597-4.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 202596-28.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025129+24.0%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 202496+6.7%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024101+13.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024134+59.5%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024104-4.6%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 202390-9.1%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 202389-10.1%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 202384-31.7%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023109-3.5%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 202299-16.1%Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q1 2020–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-zolgensma-group-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.